Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRABiotechnology
-$0.10 today
- Market cap
- $69.21M
- Beta
- 2.76
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$1.24
Volume 1.50M
Average 2.02M
NMRA Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Neumora Therapeutics, Inc. Common StockNASDAQ: NMRA
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue remains negative
Q1 FY2026 cost of revenue was $8K, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $5.01M.
Context
- Cost of revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly cost of revenue holds near $8K or moves back toward the trailing-twelve-month quarterly average of $1.25M.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 5M USD
- Year-over-year change
- —
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5M | — |
| FY2024 | 2024-12-31 | 0 | -100.0% |
| FY2023 | 2023-12-31 | 668K | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Cost of Revenue vs competitors
How NMRA compares with its peers on the latest reported figures
- NMRA's LTM Mar 2026 cost of revenue of $5.01M is the 7th highest of the 10 companies compared; the peer median is $11.12M.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $102.95M | -34.6% | — | 111.2% | |
| LTM Mar 2026 | $99.22M | -12.1% | -54.4% | 112.4% | |
| LTM Mar 2026 | $71.03M | -55.3% | — | 111.9% | |
| LTM Mar 2026 | $30.8M | — | — | 53.2% | |
| LTM Mar 2026 | $11.12M | +3594.0% | — | 112.4% | |
| LTM Mar 2026 | $7.35M | +33.7% | +32.5% | 9.3% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $5.01M | — | — | — |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $871K | +6.2% | +140.9% | 11.8% |
| LTM Mar 2026 | $646K | -97.5% | -82.7% | 0.9% | |
| LTM Mar 2026 | $338K | -99.3% | -73.7% | — | |
| Peer median (excluding NMRA) | $11.12M | -23.3% | -54.4% | 82.2% | |
Competitors are the stored peer set for NMRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 668K | 0 | 5M |
| Gross Profit | 0 | 0 | (668K) | 0 | (5M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 212.78M | 104.75M | 142.72M | 200.93M | 176.07M |
| Selling, General & Admin | 24.55M | 31.12M | 44.81M | 62.54M | 60.09M |
| Operating Expenses | 237.32M | 135.87M | 187.53M | 263.46M | 236.16M |
| Depreciation & Amortization | 538K | 594K | 668K | 631K | 208K |
| EBITDA | (236.77M) | (130.31M) | (234.99M) | (242.98M) | (233.37M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (237.32M) | (135.87M) | (188.19M) | (263.46M) | (241.16M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 4.56M | 16.61M | 19.93M | 8.34M |
| Interest Expense | 0 | 0 | 0 | 0 | 3.22M |
| Other Income / Expenses | 11K | 4.97M | (47.46M) | 19.86M | 4.36M |
| Income Before Tax | (237.31M) | (130.9M) | (235.66M) | (243.61M) | (236.8M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 268K | 178K | 130K |
| Net Income | (237.31M) | (130.9M) | (235.93M) | (243.79M) | (236.93M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.56) | (0.86) | (1.49) | (1.53) | (1.45) |
| EPS (Diluted) | (1.56) | (0.86) | (1.49) | (1.53) | (1.45) |
| Weighted Avg Shares | 151.95M | 151.95M | 158.83M | 159.38M | 163.39M |
| Weighted Avg Shares (Diluted) | 151.95M | 151.95M | 158.83M | 159.38M | 163.39M |
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
Intrinsic Alpha fair value
Locked
Current Price
$0.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.